

Index

A

- abacavir (ABC).....61
- adverse effects66t, 237
 - CNS penetration-effectiveness.....224t
 - dosage guidelines.....62t
 - FDA Black Box warnings,.....69t
 - HIV-1-associated dementia.....223
 - hypersensitivity.....61, 108–109, 119
 - + lamivudine (Kivexa™).....61, 62t, 66t
 - methadone interactions.....87t
 - pregnant patients.....84
 - + zidovudine + lamivudine (Trizivir™).....61, 64, 223
- ABC. See abacavir
- ABVD regimen.....209
- acalculous cholecystitis.....186
- Acanthamoeba.....180
- accessory proteins (HIV).....9, 10t
- aciclovir
- herpesviridae infections.....194, 198, 199, 199t, 260
 - oral hairy leukoplakia.....191
 - resistance.....198–199
 - retinal necrosis.....259
- acid/base disturbances.....240, 241t
- acquired immune deficiency syndrome. See AIDS
- activation signals.....19
- acute demyelinating polyneuropathy.....220–221
- acute primary illness.....39
- antiretroviral therapy for.....80, 80t, 114
 - clinical features.....125, 126t
 - diagnosis of.....73, 74t–75t, 125–126, 127f
 - prognostic markers in.....40–41, 80
- acute retinal necrosis.....259, 259f
- acute retroviral syndrome (ARVS). See acute primary illness
- ADCC (antibody-dependent cellular cytotoxicity).....24
- Addison's disease.....253t, 254
- adefovir dipivoxil.....83, 267
- adherence, to antiretroviral therapy.....60, 93–94, 94t, 113, 119
- adipose tissue
- subcutaneous (SAT).....104t
 - visceral (VAT).....104t, 105
- adjustment disorder.....242
- adrenal disease, 253t.....254
- adverse drug eruptions.....203–204, 205t
- Africa
- HIV epidemic in.....13f, 14
 - HIV lineages-groups in.....11–12
- age factors
- immune restoration and.....130
 - progressive multifocal leucoencephalopathy.....168
- agoraphobia.....244
- AIDS.....39, 128
- epidemiology of.....13–14
 - rate of progression to.....40, 85
- AIDS-associated cholangiopathy.....186
- AIDS-defining illness (AI).....39, 128, 128t–129t
- See also opportunistic infections; specific illness
- cART initiation and.....77–78, 78t
- AIDS-NHL. See non-Hodgkin's lymphoma
- AIN (anal intraepithelial neoplasia).....210–211
- airflow limitation, chronic.....181
- alcohol abuse.....242, 246, 274
- alfalFN (interferon-alpha).....168, 254, 267
- algorithms
- ARVS diagnosis.....125, 127f
 - cardiovascular risk assessment.....106f
 - HBV co-infection management.....266, 266f–267f
 - HCV co-infection management.....272, 272t, 273f
 - neurological conditions.....217, 218t
 - post-exposure prophylaxis.....120t, 120–122
 - resistance interpretation.....95, 97
- alpha-chemokines (CXC chemokines).....21
- alpha-defensins.....23
- amenorrhoea, secondary.....255
- amphotericin B.....231, 232
- adverse effects.....157t
 - cryptococcosis.....157, 201
 - oesophageal candidiasis.....142
 - oropharyngeal candidiasis.....192–193, 193t
 - penicilliosis.....177, 201
- amprenavir.....87t, 108–109
- anaemia.....261
- anal cancer.....210–210
- analgesics.....249, 250
- anal intraepithelial neoplasia (AIN).....210–211
- androgen deficiency.....253t, 254–255
- anergy.....28, 28f
- reversal of.....30t, 30–31
- angular cheilitis.....192, 200
- ankylosing spondylitis.....249
- antibodies (HIV). See also specific antibody
- binding.....24, 49
 - neutralising.....24, 26, 49
- antibody-dependent cellular cytotoxicity (ADCC).....24
- antidepressants.....243, 245
- drug interactions.....247t, 248
- antifungal agents. See also specific drug
- adverse effects.....157t
 - candidiasis.....201
 - oesophageal.....141–142, 143t, 184
 - oropharyngeal.....192–193, 193t
 - cryptococcosis.....157, 201
 - dermatological infections.....200–201
- antigens (HIV). See also specific antigen

- assays for.....51
- presentation and recognition..... 19, 22, 25, 288
- anti-inflammatory agents, for immune restoration disease..... 290
- antimicrobial agents. See also specific drug
 - adverse effects..... 136t, 147t, 155t
 - antiretroviral interactions with..... 145, 146t, 147
 - resistance..... 148
- antipsychotic drugs..... 245, 246
 - drug interactions..... 247t, 248
- antiretroviral therapy (ART), 59–69. See also specific drug or drug class
 - acute HIV infection..... 80, 80t
 - adherence to..... 60, 93–94, 94t, 113, 119
 - CD4 cell response..... 23, 24, 27–28
 - CD8 cell response..... 22
 - changing..... 97–100
 - children..... 85t, 85–86
 - CNS penetration-effectiveness..... 223, 224t, 245–246
 - coformulations..... 61, 62t
 - combination (highly active) See combination antiretroviral therapy
 - contraindications..... 66t, 79, 80t
 - dosage guidelines..... 62t, 63t, 65t, 66t
 - drug classes..... 60–64
 - drug interactions See drug interactions; specific drug
 - failure of..... 94–95, 95t, 97–99, 114
 - FDA Black Box warnings..... 68, 69t
 - goals of..... 60, 77, 94
 - guidelines..... 59–61, 64, 77, 79, 85–86, 113
 - hepatitis B co-infection..... 82–83, 108
 - hepatitis C co-infection..... 81–82
 - historical perspective..... 59–60, 77
 - HIV-associated dementia..... 86, 86t, 222–223
 - HIV-associated nephropathy..... 240
 - induction-maintenance strategies..... 80–81
 - initiation of..... 77–89
 - indications for..... 78t, 80t
 - interruption of..... 81, 100, 114
 - limitations of..... 29
 - monitoring of..... 93, 93t
See also therapeutic drug monitoring
 - non-AIDS events and..... 42–43, 78
 - post-exposure See post-exposure prophylaxis
 - pregnant patients..... 83–85
 - regimens..... 64, 79, 79t
 - resistance to See drug resistance
 - salvage therapy 99–100, 100t
 - toxicity..... 64–68, 99, 110t
See also specific adverse effect
 - management of..... 103–110, 110t
 - post-exposure prophylaxis..... 119
 - risk-benefit analysis..... 60
 - vertical transmission and..... 39, 83–85, 114
- antituberculous agents..... 150–151
- antiviral agents. See antiretroviral therapy; specific drug or infection
- anxiety..... 242, 244–245
- aplaviroc..... 109
- APOBEC system..... 30
- apoptosis
 - CD4, HIV-induced..... 27, 27t, 28
 - programmed (PD)..... 28
- arrhythmias..... 239
- ART. See antiretroviral therapy; specific drug
- ART Cohort Collaboration..... 77, 78
- arterial blood gas analysis..... 134, 175
- articular rheumatological disease..... 249–251
- ARVS (acute retroviral syndrome). See acute primary illness
- Asia, HIV lineages-groups in..... 11–12
- Aspergillus..... 177, 180
- assembly (HIV)..... 11
- asymptomatic chronic illness..... 39
 - antiretroviral therapy for..... 59
 - initiation guidelines..... 77–79
 - regimen choice..... 79, 79t, 99
- asymptomatic neurosyphilis..... 278–280
- atazanavir (ATV)..... 63
 - adverse effects..... 67t, 240
 - antimicrobial interactions 146t, 150
 - CNS penetration-effectiveness..... 224t
 - contraindications..... 66t, 84
 - dosage guidelines..... 63t
 - HIV-1-associated dementia..... 223
 - methadone interactions..... 87t
- atorvastatin..... 106, 237
- atovaquone
 - adverse effects..... 136t, 155t
 - *P. jirovecii* pneumonia..... 134–135
 - toxoplasmosis..... 155
- Atripla™ (tenofovir + emtricitabine + efavirenz)..... 61, 62t, 66t
- ATV. See atazanavir
- Australia
 - HIV epidemic in..... 13f, 14
 - HIV seroprevalence in..... 118t
 - resource list..... 295–297
- Australian HIV Observational Database..... 130, 270
- autoimmune manifestations, of acute primary illness..... 126t, 127
- autoimmune thyroiditis..... 253t, 254, 290
- avascular necrosis..... 250–251
- azidothymidine. See zidovudine
- azithromycin
 - adverse effects..... 147t
 - bacterial pneumonia..... 176
 - Bartonella infections..... 233
 - cryptosporidiosis..... 159–160, 160t
 - MAC infection..... 145, 147
 - syphilis..... 282
 - toxoplasmosis..... 155
- AZT. See zidovudine

B

bacillary angiomatosis.....233, 233f
 back-killing.....26, 26f
 bacterial infections. See also specific infection

- diagnostic criteria.....129t
- gastrointestinal.....189–191
- pneumonia.....176
- reactive arthritis triggered by.....250
- sinusitis.....180–181

Bartonella infections.....232–233, 233f
 basal cell carcinoma.....211
 B cells

- abnormal activation of.....29
- HIV-specific responses.....23, 56t

 bDNA (branched chain DNA) assay.....50, 51f
 benzodiazepines.....246, 247t, 248
 beta-chemokines (CC chemokines).....21, 23, 25
 biliary disease

- cryptosporidiosis.....159–160
- differential diagnosis.....183t, 186

 binding (HIV).....10–11, 37
 binding antibodies.....24, 49
 bipolar illness.....245
 blepharitis.....260
 blood disorders.....261–262

- See also specific disorder

 BMD (bone mineral density).....109
 bodily fluids, transmission by.....39
 See also mother-to-child transmission; sexual
 transmission body-cavity-based lymphoma
 (primary effusion lymphoma).....207, 209
 body fat changes. See lipodystrophy
 bone disease.....109, 110t, 254
 bone-marrow biopsy.....227, 230, 262
 bone marrow transplantation.....208
 bone mineral density (BMD).....109
 bosentan.....238
 brain, productive HIV infection in.

- See HIV-1-associated dementia

 brain biopsy.....167t, 168, 169
 branched chain DNA (bDNA) assay.....50, 51f
 breast-feeding, mother-to-child transmission
 during.....39, 84–85
 bronchoalveolar lavage.....134, 175
 bronchoscopy.....134, 175
 buprenorphine.....88, 88t
 Burkitt's lymphoma (small non-cleaved-cell
 lymphoma).....207

C

Caesarean section, vertical transmission and.....84
 CAF (cell-associated factor).....23
 calcium metabolism disorders.....253t, 254
Campylobacter infection.....190
 candidiasis.....200–201

- arthritis.....250
- diagnostic criteria.....128t
- endocarditis.....239

• oesophageal See oesophageal candidiasis
 • oropharyngeal.....184, 192f, 192–193, 193t, 200
 • vulvovaginal.....200
 carbamazepine.....247t
 carcinoma

- basal cell.....211
- hepatocellular.....266, 270
- lung.....181
- squamous cell.....211

 cardiomyopathy, dilated.....237–238
 cardiovascular disease (CVD).....105–107, 106t, 110t, 237–239

- See also specific disease
- risk assessment.....105–106, 106f

 cART. See combination antiretroviral therapy
 case studies

- adherence.....94, 98
- drug resistance.....98
- hepatitis B co-infection.....82
- hepatitis C co-infection.....81
- HIV-associated dementia.....86, 217
- methadone therapy.....88
- mother-to-child transmission.....85
- new HIV diagnosis.....73
- therapeutic failure.....98

 caspofungin

- oesophageal candidiasis.....141–142
- oropharyngeal candidiasis.....193, 193t
- *P. jirovecii* pneumonia.....135

 Castleman's disease.....138, 181, 212, 212t
 catalytic proteins (HIV).....9, 10t
 cat-scratch disease.....232
 cause of death, non-AIDS events.....42–43, 78
 CC chemokine (beta-chemokine).....21, 23, 25
 CC chemokine receptor (CCR).....21
 CC chemokine receptor 2 (CCR2).....41t
 CC chemokine receptor 5 (CCR5).....10–11, 21

- mutations.....25, 41, 41t, 41f
- sexual transmission and.....37

 CC chemokine receptor 5 (CCR5)
 antagonists.....54, 60, 63–64

- See also maraviroc
- adverse effects.....65t, 109, 291
- dosage guidelines.....65t
- tropism testing.....53f, 54, 64, 96

 CCL3 chemokine.....41
 CCL5 chemokine. See RANTES
 CD4 cells.....19–20, 20f

- function.....23, 23f
- HIV-induced defects.....26–28
- HIV-specific responses.....23–24, 25
 - assays.....23, 56t
 - boosting.....30–31
- homeostasis.....27
- immune restoration.....130, 288
- memory See memory T cells
- type 1 (Th1).....19
- type 2 (Th2).....19

- CD4 cell count
- acute primary illness..... 125
 - antiretroviral guidelines by..... 59, 77–79, 78t
 - children..... 86
 - immune restoration..... 287, 289, 292
 - non-AIDS events..... 42, 78
 - pregnant patients..... 83
 - prognosis by, pre-cART era..... 77, 77f
 - as surrogate marker..... 40–41, 80
 - syphilis..... 277, 279
 - therapeutic monitoring using..... 93
 - treatment interruption guided by..... 114
- CD4 receptors..... 10, 29
- CD8 cells..... 19–20
- CD38 expression..... 40
- CD4 helper function and..... 23, 23f
- HIV-specific responses..... 21–23, 25
 - assays..... 21–22, 56t
 - boosting..... 30
- CD8 cell count..... 125
- CD14 monocytes..... 29
- CD16 monocytes..... 29
- CD38 expression..... 40
- CD40L expression..... 23
- CD45 molecule..... 20
- CDE regimen..... 208
- cell-associated factor (CAF)..... 23
- cell death
- CD4..... 27, 27t
 - programmed (PD)..... 28
- cell homeostasis (CD4 cells)..... 27
- cell proliferation (CD4)..... 27
- cellular cytotoxicity, antibody-dependent (ADCC)..... 24
- cellular immune system..... 19–21
- cellular reservoirs (HIV latency)..... 26, 31
- antiretroviral therapy and..... 59–60
- central nervous system (CNS)
- antiretroviral agents affecting 86, 86t, 222–223, 224t, 245–246
 - disease (See neurological conditions; specific disease)
 - monocytic populations in..... 29
 - treponemal penetration..... 278
- central nervous system penetration-effectiveness (CPE)..... 223, 224t, 245–246
- cerebral cryptococcosis. See cryptococcosis
- cerebral toxoplasmosis. See toxoplasmosis
- cerebrospinal fluid (CSF)..... 156, 167–169
- HIV-1-associated dementia..... 217
 - neurological conditions..... 218–219, 221
 - neurosyphilis..... 277, 279, 282
 - oncological conditions..... 208
 - VDRL..... 279
- cervical cancer..... 128t, 200, 209–210
- cervical intraepithelial neoplasia (CIN)..... 210
- chancre..... 276
- chemokine(s)..... 20–21
- See also specific chemokine
- chemokine receptors..... 10–11, 21
- See also specific receptor
- polymorphisms..... 25, 39, 41, 41t, 289
- chemotherapeutic agents. See also specific drug or protocol
- anal cancer..... 210–211
 - Hodgkin's disease..... 209
 - Kaposi's sarcoma..... 139–140
 - non-Hodgkin's lymphoma..... 208
- chicken pox..... 198
- childbirth, transmission during..... 39, 83–85
- children
- AIDS-defining illnesses in..... 129t
 - antiretroviral therapy for..... 85t, 86
 - disease progression in..... 85–86
 - HIV epidemic in..... 13, 13f
 - late presentation in..... 129
- cholangiopathy..... 186
- cholecystitis, acalculous..... 186
- CHOP regimen..... 208
- chorioretinal toxoplasmosis..... 259
- choroidal disease..... 256–259
- choroiditis, multifocal..... 259
- chronic airflow limitation..... 181
- chronic inflammatory demyelinating polyneuropathy, 220–221
- cidofovir..... 162–163, 168, 257t
- CIN (cervical intraepithelial neoplasia)..... 210
- circulating recombinant forms (CRFs)..... 12
- circumcision, sexual transmission and..... 38
- cirrhosis, with hepatitis C co-infection..... 271, 271f
- clarithromycin
- adverse effects..... 147t
 - antiretroviral dose with..... 146t
 - MAC infection..... 145, 147, 151
 - toxoplasmosis..... 155
- clindamycin..... 134, 136t, 155, 155t
- clinical assessment
- new HIV diagnosis..... 73, 74t
 - post-exposure prophylaxis..... 120, 120t
- clinical latent period..... 127
- clinical treatment failure
- antiretroviral..... 94–95, 95t, 97–99
 - cytomegalovirus disease..... 163
 - syphilis..... 282
- clofazimine..... 147t
- Clostridium difficile* infection..... 190–191
- CMV. See cytomegalovirus infection
- CNS. See central nervous system
- Coccidioides immitis*..... 174
- coccidioidomycosis..... 128t, 228t, 231
- coformulations..... 61, 62t, 66t
- See also specific drug
- cognitive-affective symptoms..... 243
- Cognitive Behavioural Therapy approach..... 245
- cognitive disorders..... 245–246
- co-infections..... 265–282
- See also specific infection

- multiple HIV strains.....38
- testing for.....126
- colitis, *Clostridium difficile*.....190–191
- combination antiretroviral therapy (cART).
See also antiretroviral therapy; specific drug
- CD4 cell response.....27–28
- CD8 cell response.....22
- contraindications.....66t, 79, 80t
- deferral of, systemic symptoms and.....227–229
- formulations.....61
- historical perspective.....59, 77
- immune restoration after.....60, 130, 287
- See also immune restoration disease
- individualisation of.....113
- influence on HIV natural history.....130
- initiation guidelines.....59–61, 64, 77, 290
- injecting and recreational drug interactions.....
.....87t–89t, 88–89
- monitoring of.....93, 93t
- post-exposure prophylaxis.....119–120
- pregnant patients,.....83–84
- regimens.....64, 79, 79t
- resistance to See drug resistance
- ritonavir boosting in.....63, 68
- toxicities.....59–61
- Combivir™ (zidovudine + lamivudine).....61, 62t, 66t, 119
- computed tomography (CT)
- cerebral toxoplasmosis.....154, 154f
- HIV-1-associated dementia.....217, 219, 219f
- primary central nervous system lymphoma.....208
- progressive multifocal leucoencephalopathy.....167t
- structural brain damage.....245
- conjunctivitis.....249
- constitutive escape.....26, 26f
- contact tracing
- HIV.....73, 75t
- syphilis.....282
- coreceptors. See also CD4 receptors; chemokine receptors
- disease progression and.....42
- for viral entry,.....10–11, 63, 64f
- coreceptor usage, detection of.....53f, 54
- coronary artery disease.....237
- corticosteroids.....30t, 134, 254, 258, 261
- cortisol responses.....253t, 254
- Corynebacterium equi*. See *Rhodococcus equi* infection
- cosmetic surgery, for facial lipoatrophy.....105
- co-stimulator molecules.....19
- cotrimoxazole (trimethoprim/sulfamethoxazole)
- adverse effects.....136t
- cryptosporiasis.....188
- hypersensitivity.....135, 135t
- Isospora infection.....188
- nocardiosis.....178
- *P. jirovecii* pneumonia.....134–135, 174, 229
- Salmonella infection.....189
- Shigella infection.....190
- toxoplasmosis.....155
- cotton wool spots.....256
- CPE (CNS penetration-effectiveness)223, 224t, 245–246
- creatinine kinase.....251
- CRFs (circulating recombinant forms).....12
- Crohn's disease.....185
- cryptococcosis.....156–158
- clinical presentation.....156, 180, 200, 228t
- dermatological.....201
- diagnosis.....128t, 156–157, 173, 227, 228t
- immune restoration disease.....156, 290, 291t
- management.....157
- meningitis.....156–158, 218, 290, 291t
- optic neuropathy.....260
- prognosis.....157
- prophylaxis.....157–158
- cryptosporidiosis.....159–160, 187
- clinical manifestations.....159, 180
- diagnosis.....128t, 159
- immune restoration disease.....159, 290
- management.....159, 160t
- prophylaxis.....159–160
- CSF. See cerebrospinal fluid
- CTL (cytotoxic T lymphocytes).....19–20, 25, 30, 56t
- C-type lectin receptors.....37
- Cushing's syndrome.....254
- cutaneous disease. See dermatological conditions;
specific disease
- cutaneous leishmaniasis.....230
- CVD (cardiovascular disease).....105–107, 110t, 237–239
- See also specific disease
- risk assessment.....105–106, 106f
- CXC chemokine (alpha-chemokine).....21
- CXC chemokine receptor (CXCR).....21
- CXC chemokine receptor 4 (CXCR4).....10–11, 21, 42
- antagonists.....54, 63–64
- Cyclospora cayetanensis infection.....187–188
- cyclosporine,.....30t, 168
- cytochrome P450 enzymes.....248
- cytokines.....19–20
- See also specific cytokine
- assays.....21–22, 23, 56t
- chemotactic See chemokine(s)
- immunomodulatory.....30, 30t
- pro-inflammatory.....29
- cytomegalovirus (CMV) infection.....161–163
- CD8 cell response.....22
- clinical presentations.....161, 180, 184, 228t
- diagnosis.....128t, 162, 173, 174t, 228t
- immune restoration disease.....289, 291t, 292
- management.....162–163, 257, 257t
- oesophageal.....194
- prophylaxis.....163
- retinitis.....161–163, 256f, 256–258, 257t, 258t, 289
- cytosine arabinoside.....168
- cytotoxicity, antibody-dependent.....24
- cytotoxic T lymphocytes (CTL).....19–20, 25, 30, 56t

D

- dapsone..... 135, 136t, 155, 155t
- darunavir (DRV)..... 61, 63
- adverse effects..... 67t
 - antimycobacterial agents combined with..... 146t
 - dosage guidelines..... 63t
 - hypersensitivity..... 108–109
 - methadone interactions..... 87t
 - salvage therapy..... 100t
- daunorubicin..... 139
- DC. See dendritic cells
- DC-SIGN (dendritic cell-specific ICAM-3-grabbing non-integrin)..... 29, 37
- ddC (zalcitabine)..... 61, 107, 220
- ddl. See didanosine
- delavirdine (DLV)..... 61
- adverse effects..... 67t
 - antimycobacterial agents combined with..... 146t
 - CNS penetration-effectiveness..... 224t
 - dosage guidelines..... 62t
- delayed-type hypersensitivity (DTH) skin tests..... 289
- delirium..... 245, 245t
- dementia. See HIV-1-associated dementia
- dendritic cells (DC)..... 19, 20
- CD4 cell priming of..... 23, 23f
 - HIV attachment to..... 37
 - sexual transmission and..... 37
 - vaccination..... 30
- dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN)..... 29, 37
- depression..... 242, 243, 244t, 273
- dermatitis, seborrhoeic..... 202
- dermatological conditions..... 197–205
- See also specific condition
- acute primary illness..... 126t, 127
 - approach to..... 197–198
 - differential diagnosis..... 197t
 - early symptomatic infection..... 127
 - non-infectious..... 202–203
- dermatological infections
- fungal..... 200–201
 - parasitic..... 202
 - viral..... 197–200
- dermatological neoplasms..... 211
- dermatophyte infections..... 200
- DEXA (dual-energy X-ray absorptiometry)..... 103
- diabetes mellitus(DM)..... 105, 110t, 253t, 253–254
- diagnostics..... 49–57
- See also specific test
- acute primary illness..... 125–126
 - dermatological conditions..... 197, 197t
 - immune restoration disease..... 290
 - immunological..... 56, 56t
 - infants..... 85
 - new HIV diagnosis..... 73, 74t–75t
 - post-exposure prophylaxis..... 122, 122t
 - systemic symptoms..... 227, 228t–229t
 - therapeutic drug monitoring..... 56–57
 - virological..... 24, 49–54, 85
- diarrhoeal illness..... 184–185
- acute..... 184
 - antiretroviral-induced..... 185
 - Campylobacter..... 190
 - chronic..... 184–185
 - Clostridium difficile..... 190–191
 - cryptosporidial..... 159, 187
 - Cyclospora..... 187–188
 - differential diagnosis..... 183t
 - Giardia..... 188–189
 - Isospora..... 188
 - microsporidial..... 165, 187
 - reactive arthritis triggered by..... 250
 - Salmonella..... 189
 - Shigella..... 189–190
- didanosine (ddl)..... 61
- adverse effects..... 61, 66t, 107, 108, 220, 237, 273
 - CNS penetration-effectiveness..... 224t
 - contraindications..... 61, 66t, 80t, 84, 119
 - dosage guidelines..... 62t
 - FDA Black Box warnings..... 69t
 - methadone interactions..... 87t
- diffuse infiltrative lymphocytosis syndrome (DILS)..... 181, 251
- diffuse large B-cell lymphoma..... 207
- dilated cardiomyopathy..... 237–238
- DILS (diffuse infiltrative lymphocytosis syndrome)..... 181,251
- directly observed therapy (DOT)..... 150
- discordant immune response..... 60
- disease progression (HIV)..... 39–42
- CD4 cell response and..... 24
 - CD8 cell response and..... 22–23
 - children..... 85–86
 - gender differences in..... 42, 78, 83
 - hepatitis B co-infection..... 265–266
 - hepatitis C co-infection..... 270–271
 - host factors influencing..... 25, 30, 40, 41–42
 - long-term non-progressors (LTNP)..... 25, 40
 - neutralising antibodies and..... 24, 26, 49
 - phases of..... 39
 - rates of..... 40, 85
 - risk assessment..... 77, 80
- See also prognosis
- surrogate markers of..... 40–41, 80
 - therapeutic failure and..... 95, 97–99, 114
 - viral factors influencing..... 42
- DLV. See delavirdine
- DM (diabetes mellitus)..... 105, 110t, 253t, 253–254
- DOT (directly observed therapy)..... 150
- doxorubicin..... 139
- drug eruptions..... 203–204, 205t
- See also specific drug
- drug hypersensitivity, 108–109, 110t. See also specific drug
- drug interactions, with antiretroviral therapy..... 68, 68t, 81
- antacids,..... 184
 - antimicrobial agents..... 145, 146t, 147, 150
 - injecting..... 87t–89t, 88–89
 - psychoactive agents..... 46, 247t, 248
- drug reactions..... 227, 228
- See also specific drug

- drug-related arthropathy.....250
- drug resistance. See also specific drug
- HIV subtypes.....13, 52, 52t
 - regimen changes and.....99
 - testing for.....53–54, 95–97
 - indications for.....97, 99t
 - interpretation of.....96–97, 97t
- drug use. See injecting drug use; substance abuse
- DRV. See darunavir
- d4T. See stavudine
- DTH (delayed-type hypersensitivity) skin tests.....289
- dual-energy X-ray absorptiometry (DEXA).....103
- dual HIV infection.....38
- dysentery, Shigella.....189–190
- dyslipidaemia.....105–107, 110t, 237
- dysphagia.....184, 193
- ## E
- early symptomatic (HIV) infection.....127–128
- EBV (Epstein Barr virus).....191, 207, 208
- echocardiography.....238
- Ecstasy (methylenedioxy-methamphetamine).....88–89
- efavirenz (EFV).....61
- adverse effects.....67t, 68, 185, 243
 - antimicrobial interactions with.....146t, 150
 - cardiovascular disease induced by.....105–107
 - CNS penetration-effectiveness.....224t
 - contraindications.....66t, 79, 80t, 84, 119
 - dosage guidelines.....62t
 - dosing.....61
 - as initial therapy.....79, 79t
 - methadone interactions.....87t
 - + tenofovir + emtricitabine (Atripla™).....61, 62t, 66t
 - toxicity.....109
- effector cells.....19–20, 20f, 22
- EFV. See efavirenz
- electrocardiography.....239
- electrolyte abnormalities.....240, 241t
- ELISA (enzyme-linked immunosorbent assay)
- hepatitis C infection.....270, 278
 - HIV infection.....24, 49, 125–126
 - syphil.....278
- ELISPOT (enzyme-linked immunospot assay)
- HIV infection.....21, 23, 56t
 - M. tuberculosis infection.....150, 174
- elite controllers.....25, 40
- elvitegravir (EVG).....52t
- emphysema.....181
- emtricitabine (FTC).....61
- adverse effects.....66t
 - CNS penetration-effectiveness.....224t
 - contraindications.....80t
 - dosage guidelines.....62t
 - FDA Black Box warnings.....69t
 - hepatitis B co-infection.....78–79, 83, 108, 267
 - post-exposure prophylaxis.....119
 - + tenofovir (Truvada™).....60, 61, 62t, 66t, 119
 - + tenofovir + efavirenz (Atripla™).....61, 62t, 66t
- Encephalitozoon intestinalis.....165, 180
- encephalopathy.....29, 128t
- endocarditis.....239
- endocrine disorders.....253t, 253–255
- See also specific disorder
- enfuvirtide (ENF or T-20).....64
- adverse effects of.....64, 64t
 - CNS penetration-effectiveness.....224t
 - dosage guidelines.....65t
 - injection site reactions.....110t
- entecavir.....268
- enteritis. See gastrointestinal infections; specific infection
- Enterococcus, vancomycin-resistant (VRE).....191
- Enterocytozoon bieneusi.....165
- enteropathy.....185
- enthesopathy.....249
- entry inhibitors.....11, 60, 63–64
- entry pathways.....27
- envelope proteins (HIV).....9, 9f, 10, 24, 37, 50, 63
- enzyme-linked immunosorbent assay (ELISA).....24, 49, 125–126, 270, 278
- enzyme-linked immunospot assay (ELISPOT).....21, 23, 56t, 150, 174
- eosinophilic folliculitis.....203, 204t
- epitope deletion.....25
- EPOCH regimen.....208
- Epstein Barr virus (EBV).....191, 207, 208
- ERCP (endoscopic retrograde cholangiography).....186
- erythema multiforme.....203, 205t
- erythematous candidiasis.....192
- erythromycin.....176, 190, 233
- ethambutol.....145, 147, 147t, 150
- etravirine (ETV).....61, 63
- adverse effects.....67t
 - antimycobacterial agents combined with.....146t
 - contraindications.....66t
 - dosage guidelines.....62t
 - methadone interactions.....87t
 - resistance mutations.....63
 - salvage therapy.....100t
- EVG (elvitegravir).....52t
- exit pathways, alterations to.....27–28
- eye disorders. See ophthalmic disease; specific disorder
- ezetimide.....106, 237
- ## F
- faecal samples. See stool examination
- failure of therapy
- antiretroviral.....94–95, 95t, 97–99, 114
 - cytomegalovirus disease.....163
 - syphilis.....282
- false-negative test results
- HIV.....125
 - neurosyphilis.....279
- false-positive test results
- HIV, 49–50.....126
 - neurosyphilis.....278

- famciclovir..... 198, 199, 199t
 Fanconi's syndrome..... 109
 Fas ligand (FasL)..... 20, 22, 26, 27, 29
 fat malabsorption..... 184
 female hypogonadism..... 255
 fever..... 227, 228t–229t
 fibrates..... 237
 fibrosing cholestatic hepatitis..... 265–266
 fixed-dose combination tablets..... 61, 62t, 66t
 See also specific drug
 flavivirus GB virus-C (GBV-C)..... 42
 flow cytometry..... 21, 23
 fluconazole
 • adverse effects..... 157t
 • coccidioidomycosis..... 231
 • cryptococcosis..... 157, 201
 • histoplasmosis..... 232
 • oesophageal candidiasis..... 141–142, 143t, 184
 • oropharyngeal candidiasis..... 192–193, 193t
 • resistance..... 142, 192–193, 193t
 flucytosine..... 157, 157t, 201
 fludarabine..... 168
 fluorescent treponemal antibody absorption test
 (FTA-Abs)..... 278–279
 5-fluorouracil..... 168, 210
 focal deficits, differential diagnosis of..... 217, 217t
 folic acid..... 259
 follicular disruption (type II)..... 29
 follicular disruption (type III)..... 29
 follicular hyperplasia (type I)..... 29
 folliculitides, inflammatory..... 203, 204t
 fosamprenavir (FPV or FOS)..... 63
 • adverse effects..... 67t
 • antimycobacterial agents combined with..... 146t
 • CNS penetration-effectiveness..... 224t
 • dosage guidelines..... 63t
 • for HIV-1-associated dementia..... 223
 foscarnet
 • cytomegalovirus disease..... 162–163, 257t, 257–258, 258t
 • herpes zoster..... 199
 • oesophageal ulceration..... 194
 • retinal necrosis..... 259
 fourth-generation (HIV) assays..... 126
 FPV. See fosamprenavir
 Framingham equation..... 105–106
 FTA-Abs (fluorescent treponemal antibody
 absorption test)..... 278–279
 FTC. See emtricitabine
 fungal infections. See also specific infection
 • dermatological..... 200–201
 • immune restoration disease..... 290
 • sinusitis..... 180–181
 fusion inhibitors..... 10, 60, 64
 See also enfuvirtide
 • adverse effects of..... 64, 64t
 • CNS penetration-effectiveness..... 224t
 • dosage guidelines..... 65t
- G**
 gag proteins..... 11, 24, 50
 gamma-delta T cells..... 29
 ganciclovir
 • cytomegalovirus disease... 162–163, 257t, 257–258, 258t
 • oesophageal ulceration..... 194
 • resistance..... 163
 • retinal necrosis..... 259
 gastrointestinal infection..... 187–191
 See also specific disease
 • bacterial..... 189–191
 • parasitic..... 187–189
 • reactive arthritis triggered by..... 250
 gastrointestinal symptoms..... 183–194
 • acute primary illness..... 126t
 • differential diagnosis..... 183, 183t
 • early symptomatic infection..... 128
 gastrointestinal tract
 • lymphoid changes..... 27, 40
 • mucosal changes..... 28, 184–185
 gastro-oesophageal reflux disease (GORD)..... 184
 GBV-C (flavivirus GB virus-C)..... 42
 GCSF (granulocyte colony stimulating factor)..... 262
 gender differences. See also men; women
 • in disease progression..... 42, 78, 83
 • treatment guidelines..... 83
 generalised anxiety disorder..... 244
 genetic polymorphisms
 • chemokine receptor..... 25, 39, 41, 41t, 289
 • immune restoration disease..... 289
 genetics (host)
 • HIV transmission and..... 25, 39
 • immune restoration disease..... 289, 291
 genitourinary manifestations, acute primary illness... 126t
 genomic organisation (HIV)..... 9–10, 10t
 genotyping, resistance..... 53–54, 95–97, 97t, 100
 germinal centres..... 20, 29
 GH (growth hormone), for lipodystrophy..... 104t, 105
 GHRH (growth hormone-releasing hormone)
 lipodystrophy..... 104t, 105
 Giardia lamblia infection..... 188–189
 gingivitis..... 191, 191f
 GI tract. See gastrointestinal tract
 global pandemic (HIV)..... 13f, 13–14
 • by lineages and subtypes..... 11–12
 glomerular lesions..... 240, 241t
 glucocorticoids..... 251, 254
 glucose metabolism disorders..... 253–254
 goitre..... 255
 GORD (gastro-oesophageal reflux disease)..... 184
 gp41 protein..... 9, 9f, 10, 24, 29, 50
 • entry inhibitors bindin..... 63, 64
 gp120 protein..... 9, 9f, 10, 24, 27, 29, 37, 50, 261
 • entry inhibitors binding to..... 63
 gp160 protein..... 24, 50
 granulocyte colony stimulating factor (GCSF)..... 262
 Graves' disease..... 253t, 254, 290
 group M (Main) strain..... 11–12, 12f

- group N (non-M,non-O) strain..... 11–12
- group O (Outlier) strain..... 11–12
- growth hormone (GH), for lipodystrophy..... 104t, 105
- growth hormone-releasing hormone (GHRH), for lipodystrophy..... 104t, 105
- Guillain-Barré syndrome..... 220–221
- gum disease..... 191, 191f
- gut permeability..... 28
- ## H
- HAART (highly active antiretroviral therapy)
See combination antiretroviral therapy
- HAD. See HIV-1-associated dementia
- haematological disorders..... 261–262
See also specific disorder
- Haemophilus influenzae*..... 176, 180
- HAND (HIV-associated neurocognitive disorders)
..... 221–224, 243
- harm minimisation strategies, injecting drug users..... 88
- Hashimoto's hypothyroidism..... 253t, 254
- HAV (hepatitis A virus)..... 185–186
- HBeAG (hepatitis B envelope antigen)..... 265
- HBsAG (hepatitis B surface antigen)..... 265
- HBV
See hepatitis B virus co-infection
- HCC (hepatocellular carcinoma)..... 266, 270
- HCV. See hepatitis C virus co-infection
- HD (Hodgkin's disease)..... 209, 209t
- HDL (high-density lipoprotein)..... 105–106, 237
- headache
• persistent..... 227
• in syphilis..... 277
- health care workers, occupational exposure in..... 117–118
- heart disease. See cardiovascular disease; specific disease
- heart transplantation..... 238
- Helicobacter pylori* infection..... 184
- helper T cells (CD4)
See CD4 cells
- hepatic disorders. See also under liver
• differential diagnosis..... 183t
- hepatic fibrosis, idiopathic..... 108
- hepatic flares..... 266, 268
- hepatitis..... 185–186
• ART-induced..... 82, 108, 108t
• fibrosing cholestatic..... 265–266
• peliosis..... 233
• resource list..... 296
- hepatitis A virus (HAV)..... 185–186
- hepatitis B envelope antigen (HBeAG)..... 265
- hepatitis B surface antigen (HBsAG)..... 265
- hepatitis B virus (HBV) co-infection..... 185–186, 265–268
• diagnosis..... 122, 122t, 265
• disease progression..... 265–266
• epidemiology and pathogenesis..... 265
• immune restoration disease..... 266, 290
• management..... 78–79, 82–83, 108, 266f–267f, 266–268
- hepatitis B virus (HBV) DNA..... 265, 266
- hepatitis C virus (HCV) co-infection..... 185–186, 270–274
• diagnosis..... 122, 122t, 270
• disease progression..... 270–271, 271f
• epidemiology..... 270
• immune restoration disease..... 271, 290
• management..... 81–82, 271–274, 272t, 273f
• prevention..... 274
- hepatitis C virus (HCV) RNA..... 270, 272
- hepatitis G. See flavivirus GB virus-C
- hepatocellular carcinoma (HCC)..... 266, 270
- hepatotoxicity
• antiretroviral agents..... 82, 108, 108t, 110t, 185, 266, 271
• antituberculous drugs..... 150–151
- HEPS (highly exposed but persistently seronegative)..... 24, 25
- herpes simplex virus (HSV) infection
• clinical presentation..... 199
• diagnosis..... 128t, 199
• gastrointestinal symptoms..... 184
• HIV transmission and..... 38, 199
• immune restoration disease..... 288, 289
• keratitis..... 260
• management..... 199
• oesophageal..... 194
• retinal necrosis..... 259
- herpesviridae infections. See also specific infection
• dermatological..... 197–198
• immune restoration disease..... 288, 289
- herpesvirus type 8. See human herpesvirus type 8
- herpes zoster (HZ) infection..... 198–199, 260, 288, 289
- heterosexual transmission..... 14, 37–38
See also sexual transmission
• HIV seroprevalence..... 118t
- HHV8. See human herpesvirus type 8
- high-density lipoprotein (HDL)..... 105–106, 237
- highly active antiretroviral therapy (HAART)
See combination antiretroviral therapy
- highly exposed but persistently seronegative (HEPS)..... 24, 25
- high-risk behaviours..... 242
- Histoplasma capsulatum*..... 174, 184
- histoplasmosis..... 128t, 228t, 232
- HIV
• direct detection of..... 49
• genomic organisation of..... 9–10, 10t
• immunopathology of..... 21f, 21–26
• life cycle of, 10f..... 10–11
• structure of..... 9, 9f
• taxonomy of..... 11–13, 12f
• transmission of (See transmission)
- HIV-1, 11
• assays for..... 50–51, 125
• discovery of..... 9
• life cycle of, 10f..... 10–11
• lineages..... 11–12
- HIV-2, 11
• assays for..... 50
• discovery of..... 9
- HIVAN. See HIV-associated nephropathy
- HIV antibodies, detection of..... 24, 49–50, 85, 122t, 125
- HIV-associated arthritis..... 249, 249t
- HIV-associated asymptomatic neurocognitive impairment,

-222
- HIV-1-associated dementia (HAD).....222–224
- case study.....217, 219f
 - clinical manifestations.....222, 222t, 246
 - diagnosis.....219, 219f, 222, 223t, 246
 - management.....86, 86t, 222–223, 246
 - pathogenesis of.....29
- HIV-1-associated mild neurocognitive disorder.....222
- HIV-associated minor cognitive motor disorder.....246
- HIV-associated nephropathy (HIVAN).....240, 241t
- antiretroviral initiation for.....78
 - during early symptomatic infection.....128
- HIV-associated neurocognitive disorders (HAND).....221–224, 243
- HIV co-infection.....38
- HIV core protein p24.....9, 9f, 24
- HIV DNA
- assays for.....50, 51, 51f, 85, 125
 - replicationv11
 - inhibition of.....23, 30
- HIV enteropathy.....185
- HIV infection
- CD4 cell defects.....26–28
 - clinical manifestations of.....125–130
 - diagnosis of See diagnostics; specific test
 - global pandemic of.....13f, 13–14
 - immune activation.....28–29
 - late presentation.....128–129
 - natural history of.....37–43, 125–130
 - primary illness See acute primary illness
 - progression of See AIDS; disease progression
 - resource list.....295–296
 - symptomatic (non-AIDS).....39, 42–43, 78, 127–128
 - treatment of See antiretroviral therapy; specific therapy
- HIV lipodystrophy syndrome.....68, 103–105, 104t, 110t
- HIV myelitis.....219, 220t
- HIV proteins, 9, 9f, 10. See also specific protein
- antibodies against, detection of.....24, 49–50, 85, 122t, 125
 - functions of.....11, 22, 26
- HIV RNA.....9, 9f, 11
- quantification of.....50–51, 60, 85, 125–126
- See also viral load
- HIV seroprevalence, statistics on.....118t
- HIV subtypes.....12, 12f
- disease progression and.....42
 - global pandemic by.....11–12, 14
 - phenotypic differences between.....12–13
- HIV superinfection.....38
- HIV vaccines.....13, 68–69, 115
- HLA (human leukocyte antigens).....19, 22, 25, 29, 42
- See also major histocompatibility complex
- alleles.....42, 289
- HLAB*5701.....61, 109
- HLA-B27 antigen.....249
- HLA-DR (human leukocyte antigen DR-1).....40
- HMGCoA reductase inhibitors. See statins; specific drug
- Hodgkin's disease (HD).....209, 209t
- homosexual transmission.....13–14, 38, 118
- See also men who have sex with men; sexual transmission
- HIV seroprevalence.....118t
 - human papillomavirus.....210
- host cells, infection of.....10–11
- host factors
- affecting sexual transmission.....37, 38t
 - influencing disease progression.....25, 30, 40, 41–42
- host genetics
- HIV transmission and.....25, 39
 - immune restoration disease.....289, 291
- HPV (human papilloma virus) infection. 199–200, 209–210, 290
- HSV
- See herpes simplex virus infection
- human herpesvirus type 8 (HHV8).....138–139, 181
- oncological conditions associated with...207, 209, 212
- human immunodeficiency virus. See HIV
- human leukocyte antigens. See HLA
- human papilloma virus (HPV) infection...199–200, 209–210, 290
- human tripartite motif 5 alpha (TRIM5alpha).....11, 30
- humoral immune response.....19–20, 24, 26
- hydroxyurea.....30t
- hypercalcaemia.....254
- hypercholesterolaemia.....105–107, 110t, 237
- hypergammaglobulinaemia.....29
- hyperlactataemia.....107, 108t
- hyperparathyroidism.....254
- hyperplastic candidiasis.....192, 192f, 200
- hypersensitivity, drug.....108–109, 110t
- See also specific drug
- hypertension, pulmonary.....238
- hypertriglyceridaemia.....105–107, 110t, 237
- hypoglycaemic agents.....237
- hypogonadism.....253t, 254–255
- hypothyroidism.....253t, 254
- HZ (herpes zoster) infection.....198–199, 260, 288, 289
- I
- idiopathic hepatic fibrosis.....108
- idiopathic oesophageal ulceration.....184, 193–194
- IDU. See injecting drug use
- IDV. See indinavir
- IFN. See interferon
- Ig (immunoglobulins)
- intravenous.....233, 261
 - varicella zoster virus.....198
- IL. See interleukin
- immune activation.....28–29
- immune restoration and.....287
 - limitation of.....30, 30t
 - surrogate markers of.....40, 42
- immune-based therapies.....29–31, 114–115
- immune complex glomerulonephritis.....240
- immune responses
- cellular.....19–21
 - discordant.....60
 - in highly exposed but persistently seronegative

- (HEPS) subjects..... 24, 25
- HIV-specific..... 21f, 21–25
 - assays..... 56t
 - - boosting..... 30–31
 - - viral escape from..... 25–26, 26f
 - humoral..... 19–20, 24, 26
 - non-progression and..... 25
- immune restoration (reactivation/reconstitution)..... 60, 130, 287
- immune restoration disease (IRD)..... 145, 151, 197, 287–292
- arthropathy..... 250
 - clinical presentation..... 228t, 289–290
 - cryptococcal..... 156, 290, 291t
 - cytomegalovirus..... 161, 163, 291t, 292
 - diagnosis..... 228t
 - hepatitis B virus..... 266, 290
 - hepatitis C virus..... 271, 290
 - hepatotoxicity and..... 108, 108t
 - herpesviridae infections..... 288, 289
 - human papillomavirus..... 290
 - immunological aspects of..... 287–289, 288f
 - Kaposi's sarcoma..... 139
 - management..... 290–291
 - microsporidiosis..... 165
 - mycobacterial..... 145, 151, 288, 289, 291t, 292
 - non-infectious..... 290
 - opportunistic infection prophylaxis and..... 291t, 292
 - oropharyngeal candidiasis..... 193
 - *P. jirovecii* infection..... 133, 290, 291t
 - parasitic..... 159, 290, 291t
 - progressive multifocal leucoencephalopathy..... 168, 290
 - uveitis..... 258
- immune thrombocytopenic purpura (ITP)..... 261
- immunodeficiency, reversal of..... 30t, 30–31
- immunoglobulins (Ig)
- intravenous..... 233, 261
 - varicella zoster virus..... 198
- immunological failure..... 95, 97–99, 114
- immunomodulatory cytokines..... 30, 30t
- immunopathology..... 19–31
- indeterminate Western Blot assays..... 49f, 50
- indinavir (IDV)..... 63
- adverse effects..... 63, 67t, 240, 250
 - antimycobacterial agents combined with..... 146t
 - CNS penetration-effectiveness..... 224t
 - contraindications..... 66t
 - HIV-1-associated dementia..... 223
 - methadone interactions..... 87t
- induction-maintenance strategies..... 80–81
- infants..... 84–85
- inflammatory bowel disease..... 185
- inflammatory folliculitides..... 203, 204t
- injecting drug use (IDU)
- antiretroviral therapy and..... 86–88
 - cervical cancer risk..... 209
 - hepatitis C co-infection..... 270
 - HIV seroprevalence..... 118t
 - HIV transmission through..... 12–14, 86, 118, 121, 121t
- injection site reactions (ISR)..... 110t
- insulin resistance..... 105–107, 110t, 253
- integrase..... 11
- integrase inhibitors..... 60–61, 64
- See also raltegravir
- adverse effects..... 65t, 109, 291
 - dosage guidelines..... 65t
 - drug interactions..... 150
- integration (HIV)..... 11, 26
- interferon (IFN)..... 19, 23, 266
- hepatitis co-infection..... 267, 272–273, 273t
- interferon-alpha (alfalFN)..... 168, 254, 267
- interferon alpha-2a, pegylated..... 83, 272–273, 273t
- interferon-gamma release assays..... 150, 174
- interleukin (IL)..... 19
- polymorphisms..... 41t
 - therapeutic use of..... 30, 30t, 254
- interleukin-2, recombinant (rIL-2)..... 114–115
- International AIDS Society-USA (IAS-USA) Drug Resistance Mutations..... 95
- intestinal illness
- See gastrointestinal symptoms; specific disease
- intracranial pressure (ICP)..... 157
- IRD. See immune restoration disease
- isoniazid
- adverse effects..... 147t
 - antiretroviral interactions with..... 147
 - *M. tuberculosis* infection..... 150–151
 - MAC infection..... 147
- Isospora belli infection (isosporiasis)..... 128t, 188
- ISR (injection site reactions)..... 110t
- ITP (immune thrombocytopenic purpura)..... 261
- itraconazole
- coccidioidomycosis..... 231
 - histoplasmosis..... 232
 - oesophageal candidiasis..... 141, 143t
 - oropharyngeal candidiasis..... 192–193, 193t
 - penicilliosis..... 177, 201
- ## J
- Jarisch-Herxheimer reaction..... 277, 281
- JC virus (JCV)..... 166–169

K

Kaletra

See lopinavir/ritonavir

Kaposi's sarcoma (KS)..... 138–140

 - cardiovascular..... 239, 239f
 - clinical presentations..... 138–139, 233
 - diagnosis..... 128t, 139, 174t, 175
 - gastrointestinal symptoms..... 184, 186
 - lid and conjunctival..... 260
 - management..... 139–140
 - prognosis..... 140
 - pulmonary..... 181
 - variants..... 138

keratin growth factor (KGF)..... 30

keratitis, herpes simplex virus..... 260

- keratoconjunctivitis
- Encephalitozoon..... 165
 - microsporidial..... 260
- KGF (keratin growth factor).....30
- kidney disease
- See renal disorders; specific disease
- killer T cells (CD8). See CD8 cells
- Kivexa™ (lamivudine + abacavir)..... 61, 62t, 66t
- KS
- See Kaposi's sarcoma
- L**
- lactic acidosis.....107, 185
- lactose intolerance..... 185
- lamivudine (3TC)..... 61
- + abacavir (Kivexa™)..... 61, 62t, 66t
 - adverse effects,66t
 - CNS penetration-effectiveness..... 224t
 - contraindications.....80t
 - dosage guidelines.....62t
 - FDA Black Box warnings.....69t
 - hepatitis B co-infection.....78–79, 83, 108, 267, 290
 - post-exposure prophylaxis..... 119
 - pregnant patients.....84
 - resistance to.....267
 - + zidovudine (Combivir™).....61, 62t, 66t, 119
 - + zidovudine + abacavir (Trizivir™).....61, 64, 223
- langerin.....37
- latency (HIV).....26, 31
- antiretroviral therapy and.....59–60
- latent period, clinical.....127
- latent syphilis.....277, 279–281, 281t
- late presentation.....128–129
- LDL (low-density lipoprotein).....105–106, 237
- leishmaniasis.....228t, 230f, 230–231, 290
- leukoplakia.....191, 200
- lifestyle interventions
- cardiovascular disease.....106, 237
 - diabetes.....253
 - lipodystrophy.....103, 104t
 - osteoporosis.....254
- linear gingival erythema.....191
- lip cancer.....212
- lipoatrophy.....103, 110t
- lipodystrophy.....68, 103–105, 104t, 110t, 253, 255
- lipopolysaccharide (LPS).....28, 40
- liposomal anthracyclines (LA).....139–140
- lithium.....245, 247t
- liver biopsy.....185–186, 227, 266, 271
- liver disorders. See also specific disease
- differential diagnosis.....183t
- liver transplantation.....271
- LN. See lymph nodes
- long-terminal repeat (LTR).....10, 11, 23
- long-term non-progressors (LTNP).....25, 40
- lopinavir/ritonavir (LPV/r).....63
- adverse effects.....67t, 68
 - antimycobacterial agents combined with.....146t
 - CNS penetration-effectiveness.....224t
 - dosage guidelines.....63t
 - HIV-1-associated dementia.....223
 - as maintenance monotherapy.....80
 - methadone interactions.....87t
 - post-exposure prophylaxis.....119
 - pregnant patients.....84
- low-density lipoprotein (LDL).....105–106, 237
- LP. See lumbar puncture
- LPS (lipopolysaccharide).....28, 40
- LPV/r. See lopinavir/ritonavir
- LTNP (long-term non-progressors).....25, 40
- LTR (long-terminal repeat).....10, 11, 23
- lumbar puncture (LP)
- cryptococcosis.....157
 - neurocognitive disorders.....221, 224
 - primary central nervous system lymphoma.....208
 - progressive multifocal leucoencephalopathy.....169
 - syphilis.....279–281
- lung cancer.....181, 211
- lung disease. See respiratory disease; specific disease
- lung infections, pulmonary hypertension secondary to.....238
- lung malignancy.....181
- lymphadenopathy.....262
- acute primary illness.....127
 - Castleman's disease.....212
 - MAC infection.....145
- lymph nodes (LN).....20
- CD4 cell redistribution from.....27–28
 - destruction of.....29
 - HIV replication in.....39
- lymph node biopsy.....207, 212, 227, 262
- lymphocyte(s). See B cells; T cells
- lymphocyte proliferative assays.....23, 56t
- lymphocytic interstitial pneumonitis.....129t, 181
- lymphocytosis.....125
- lymphoma
- Burkitt's (small non-cleaved-cell).....207
 - clinical presentation.....228t
 - diagnosis.....228t
 - intra-ocular.....260t
 - non-Hodgkin's See non-Hodgkin's lymphoma
 - pathogenesis.....29
 - plasmablastic.....207
 - primary central nervous system.....208–209
 - - differential diagnosis.....155, 168, 207, 208
 - primary effusion.....207, 209
- lymphopenia.....125
- M**
- MAC. See Mycobacterium avium complex
- macrolides. See also specific drug
- adverse effects.....155t
 - bacterial pneumonia.....176
 - Bartonella infections.....233
 - Campylobacter infection.....190
- macrophage inflammatory proteins (MIP).....21
- macrophages, monocyte-derived.....29

- MACS (Multicenter AIDS Cohort Study)..... 94, 125, 211
- magnetic resonance imaging (MRI)
- cerebral toxoplasmosis..... 154, 154f
 - cytomegalovirus neurological disease..... 162
 - neurological conditions..... 218
 - primary central nervous system lymphoma..... 208
 - progressive multifocal leucoencephalopathy..... 166f, 167, 167t, 169
 - structural brain damage..... 245
- magnetic resonance spectroscopy (MRS)..... 223
- maintenance strategies..... 80
- major histocompatibility complex (MHC)..... 19, 25, 26, 29
- See also HLA
- Malassezia furfur* infection..... 201, 202
- male hypogonadism..... 253t, 254–255
- malignancies
- See oncological conditions; specific malignancy
- mania..... 245
- Mantoux test (tuberculin skin test)..... 149–150, 174
- marantic endocarditis..... 239
- maraviroc..... 61, 64
- adverse effects..... 65t, 109
 - antimycobacterial agents combined with..... 146t
 - coreceptor usage testing..... 54
 - dosage guidelines..... 65t
 - FDA Black Box warnings..... 69t
 - methadone interactions..... 87t
 - salvage therapy..... 100t
- maturation inhibitors..... 64
- M-BACOD regimen..... 208
- MC (molluscum contagiosum)..... 197, 260, 290
- mDC (myeloid dendritic cells)..... 19f
- MDMA (methylenedioxy-methamphetamine)..... 88–89
- MDR (multidrug resistance, HIV)..... 60–61, 114
- membrane proteins (HIV)..... 9, 9f
- memory T cells..... 20, 22, 23, 23f
- immune restoration and..... 288
 - loss of..... 26, 27
 - non-progression and..... 25
 - proliferation of..... 27
 - qualitative defects in..... 28
- men
- circumcision of..... 38
 - disease progression in..... 42, 78, 83
- meningitis
- coccidioidomycosis..... 231
 - cryptococcal..... 156–158, 218, 290, 291t
 - histoplasmosis..... 232
- meningovascular syphilis..... 277
- menstrual disorders..... 255
- mental disorders
- See psychiatric symptoms; specific disorder
- men who have sex with men (MSM)
- See also homosexual transmission
- anal cancer in..... 210
 - HCV co-infection in..... 270, 274
 - HIV seroprevalence in..... 118t
 - HIV transmission in..... 13–14, 38, 118
 - psychological issues..... 242–243
 - STI screening for..... 122, 122t
 - syphilis in..... 276
- metformin..... 104t, 105, 107, 253
- methadone..... 87t, 88
- methicillin-resistant *Staphylococcus aureus* (MRSA)..... 191
- methotrexate, 208..... 250
- methylenedioxy-methamphetamine (MDMA)..... 88–89
- MHC (major histocompatibility complex)..... 19, 25, 26, 29
- See also HLA
- microbial translocation, HIV-induced..... 28
- microsporidiosis..... 165, 187
- clinical presentation..... 165
 - diagnosis..... 165
 - keratoconjunctivitis..... 260
 - management..... 165
 - prophylaxis..... 165
- midazolam..... 247t
- migrant populations, HIV epidemic in..... 13–14
- mild neurocognitive disorder (MND)..... 222
- minor cognitive motor disorder..... 246
- minority populations, HIV epidemic in..... 13–14
- MIP (macrophage inflammatory proteins)..... 21
- mitomycin C..... 210–211
- MND (mild neurocognitive disorder)..... 222
- molluscum contagiosum (MC)..... 197, 260, 290
- monkey models..... 28
- See also simian immunodeficiency virus
- monoclonal antibodies. See specific antibody
- monocyte-derived macrophages..... 29
- mononeuritis multiplex..... 221
- mood disorder..... 245
- mood stabilisers..... 245, 247t, 248
- MOPP regimen..... 209
- mother-to-child transmission (MTCT)..... 39, 83–85, 114, 129
- MRI. See magnetic resonance imaging
- MRS (magnetic resonance spectroscopy)..... 223
- MRSA (methicillin-resistant *Staphylococcus aureus*)..... 191
- MSM
- See men who have sex with men
- MTCT (mother-to-child transmission)..... 39, 83–85, 114, 129
- mucocutaneous leishmaniasis..... 230
- mucosal barrier, sexual transmission through..... 37
- mucosal changes
- gastrointestinal..... 28, 184–185
 - HIV-induced..... 28
- mucous membrane exposure..... 118, 121, 121t
- Multicenter AIDS Cohort Study (MACS)..... 94, 125, 211
- multicentric Castleman's disease..... 138, 181, 212, 212t
- multidrug resistance, HIV (MDR)..... 60–61, 114
- multifocal choroiditis..... 259
- musculoskeletal manifestations
- acute primary illness..... 126t
 - early symptomatic infection..... 128
- mutation(s)
- chemokines..... 25, 29, 41, 41t
 - resistance See drug resistance
- mutational escape..... 25–26, 26f
- myalgia..... 249
- mycetoma..... 177

- mycobacterial disease. See also specific disease
- diagnosis..... 129t, 227
 - gastrointestinal symptoms..... 184
 - immune restoration..... 151, 288, 289, 291t, 292
- Mycobacterium avium* complex (MAC)..... 145–148
- clinical presentation..... 145, 228t, 233, 259
 - diagnosis..... 145, 148, 173, 174t, 228t
 - immune restoration disease..... 289, 291t, 292
 - management..... 145–147
 - prognosis..... 147
 - prophylaxis..... 147–148, 227, 229, 291t, 292
- Mycobacterium tuberculosis* infection..... 149–151
- clinical presentation..... 149, 228t
 - diagnosis..... 129t, 149–150, 173, 174t, 175, 228t
 - drug resistance..... 150–151
 - immune restoration disease..... 151, 289
 - management..... 147, 150
 - prognosis..... 151
 - prophylaxis..... 151, 174
- mycophenolate mofetil..... 30t
- mycoses
- See fungal infections; specific disease
- myelitis..... 219, 220t
- myelodysplasia..... 261–262
- myeloid dendritic cells (mDC)..... 19f
- myocardial ischaemia..... 106, 237
- myocarditis..... 238, 238f
- myopathies..... 251, 251t
- N**
- naïve patient, antiretroviral initiation in..... 77–89
- indications for..... 78t, 80t
- naïve T cells
- immune restoration and..... 287
 - qualitative defects in..... 28
- NAM (nucleoside analogue mutation)..... 96
- NASBA (nucleic acid sequence-based amplification) technology based assay..... 50, 51
- natural history (HIV infection)..... 37–43, 125–130
- natural killer (NK) cells..... 20
- necrotising ulcerative periodontitis..... 191, 191f
- needle-stick injuries..... 117–118, 119t, 121, 121t
- Nef protein..... 11, 22, 26, 29
- nelfinavir (NFV)..... 63, 84, 224t
- neonates..... 84–85
- nephropathy. See HIV-associated nephropathy
- nephrotoxicity, 109, 110t
- nerve conduction studies..... 221
- neurocognitive disorders, HIV-associated (HAND)..... 221–224, 243
- neurological conditions..... 217–224
- See also specific condition
- acute primary illness..... 126t, 127
 - advanced immunodeficiency..... 168
 - approach to..... 217t, 217–219, 218f
 - cytomegalovirus..... 161–163
 - early symptomatic infection..... 128
 - nocardiosis..... 178
 - optic..... 260
- neurosyphilis..... 277–278
- diagnosis..... 279–280
 - early (ENS)..... 277, 279–281, 281t
 - treatment..... 281–282
- neutralising antibodies..... 24, 26, 49
- neutropenia..... 261–262
- nevirapine (NVP)..... 61
- adverse effects..... 67t, 82
 - antimycobacterial agents combined with..... 146t
 - CNS penetration-effectiveness..... 224t
 - contraindications..... 61, 66t, 119
 - dosage guidelines..... 61, 62t, 79
 - FDA Black Box warnings..... 69t
 - hepatotoxicity..... 108, 108t, 266
 - hypersensitivity..... 108–109
 - as initial therapy..... 79, 79t
 - mechanism of action..... 61
 - methadone interactions..... 87t, 88
 - pregnant patients 84
- new HIV diagnosis..... 73, 74t–75t
- See also acute primary illness
- infants..... 85
- NFV. See nelfinavir
- NHL. See non-Hodgkin's lymphoma
- night sweats..... 227
- nitazoxanide..... 159, 160t
- NK (natural killer) cells..... 20
- NNRTI. See non-nucleoside reverse transcriptase inhibitors
- nocardiosis..... 177–178, 178f
- non-AIDS HIV infection..... 39, 42–43, 78, 127–128
- non-Hodgkin's lymphoma (NHL)..... 207–208
- aetiology..... 207
 - cardiovascular..... 239
 - clinical presentation..... 207
 - diagnosis..... 128t, 173, 174t, 207–208
 - epidemiology..... 207
 - gastrointestinal symptoms..... 184
 - management..... 208
 - respiratory symptoms..... 181
- non-intact skin exposure..... 118, 121, 121t
- non-nucleoside reverse transcriptase inhibitors (NNRTI), 60–63
- See also specific drug
- adverse effects..... 67t, 82
 - assays..... 56–57
 - CNS penetration-effectiveness..... 224t
 - contraindications..... 79, 80t
 - dosage guidelines..... 61, 62t
 - drug interactions..... 248
 - hypersensitivity..... 108–109
 - as initial therapy..... 79, 79t
 - injecting and recreational drug interactions..... 87t–89t, 88–89
 - regimens based on, versus PI-based..... 79
 - resistance mutations..... 96

- therapeutic drug monitoring.....113
 - non-occupational exposure..... 118–119, 119t
 - management algorithm..... 120t, 120–122
 - non-occupational post-exposure prophylaxis (NPEP),
..... 117, 119–120
 - non-syncytium inducing (NSI) variants.....42
 - Norwegian scabies.....202
 - notifiable AIDS-defining illnesses.....128, 128t–129t
 - NPEP (non-occupational post-exposure prophylaxis),
..... 117, 119–120
 - NRTI. See nucleoside reverse transcriptase inhibitors
 - NSI (non-syncytium inducing) variants.....42
 - nuclear factor (NF).....11
 - nucleic acid quantification..... 50–51, 60, 85, 125
 - nucleic acid sequence (HIV).....10
 - nucleic acid sequence-based amplification (NASBA)
technology based assay.....50, 51
 - nucleoside analogue mutation (NAM).....96
 - nucleoside reverse transcriptase inhibitors (NRTI).....60, 61
See also specific drug
 - adverse effects61, 66t, 103, 104t, 107–108, 253
 - CNS penetration-effectiveness..... 224t
 - dosage guidelines.....61, 62t
 - drug interactions.....150
 - hepatitis B co-infection.....266–268
 - hepatotoxicity.....185, 266, 271
 - historical perspective.....59, 77
 - neurological toxicity.....220
 - resistance mutations.....95–96
 - NVP. See nevirapine
 - nystatin.....192
- O**
- OC. See oesophageal candidiasis
 - occupational exposure.....117–118
 - management algorithm.....120t, 120–122
 - ocular syphilis.....260, 260t, 278
 - odynophagia.....184, 193
 - oesophageal candidiasis (OC).....141–142
 - clinical presentation.....141, 184
 - diagnosis.....128t, 141
 - fluconazole refractory.....142, 142f
 - management.....141–142, 143t, 184
 - oesophageal disease.....184, 193–194, 194t
 - differential diagnosis.....183t, 184
 - OHL (oral hairy leukoplakia).....191
 - OI. See opportunistic infections; specific infection
 - olanzapine.....247t
 - oncological conditions.....207–212
See also specific disease
 - onychomycosis.....200
 - ophthalmic disease.....256–260
See also specific disorder
 - in acute primary illness.....126t
 - cytomegalovirus..161–163, 256f, 256–258, 257t, 258t, 289
 - external infections.....260
 - Reiter's syndrome.....249–250, 250f, 260t
 - toxoplasmosis.....155
 - varicella zoster virus.....198
 - opportunistic infections.....128, 133–169
See also AIDS-defining illness; specific infection
 - influence of cART on.....130
 - prophylaxis for
 - cessation following immune
restoration and.....287–288, 291t, 292
 - deferral in setting of systemic symptoms
and.....227–229
 - risk for
 - CD4 cell surrogate markers of.....40
 - children.....85
 - rationale for initiation of antiretroviral therapy and.....59
 - optic neuropathy.....260
 - oral aphthous ulceration.....191–192
 - oral disease.....191–193
 - oral hairy leukoplakia (OHL).....191
 - oral manifestations. See also specific disorder
 - acute primary illness.....126t
 - early symptomatic infection.....127–128
 - oral sex, HIV transmission through.....39
 - oropharyngeal candidiasis...184, 192f, 192–193, 193t, 200
 - osteoporosis.....109, 110t, 253t, 254
 - otologic syphilis.....278
- P**
- p6 protein.....11
 - p17 protein.....24
 - p24 protein.....9, 9f, 24
 - antigen assays.....50, 51, 125–126
 - p31 protein.....24
 - p51 protein.....24, 50
 - p55 protein.....24, 50
 - p66 protein.....24, 50
 - p88 protein.....24
 - paclitaxel.....139–140
 - PACTG 076 study.....83
 - paediatric patients.....84–86
 - painful articular syndrome.....249
 - pancreatitis.....183t
 - pancreatobiliary cryptosporidiosis.....159–160
 - pancytopenia.....261–262
 - papillary duct stenosis.....159, 186
 - papilloedema.....260
 - Pap smears.....210
 - paraproteinaemia.....262
 - parasitic infections. See also specific infection
 - dermatological.....202
 - gastrointestinal.....187–189
 - immune restoration disease.....290
 - parathyroid hormone (PTH).....254
 - paromomycin.....160t
 - parvovirus B19 infection.....233–234
 - pathogen-specific responses, immune
restoration and,287–289, 292
 - patient adherence, to antiretroviral therapy
.....60, 93–94, 94t, 113, 119
 - patient education, new HIV diagnosis.....73, 74t

- PBMC (peripheral blood mononuclear cells)..... 51
- PBS (Pharmaceutical Benefits Scheme), Section 100 (s100), 83, 100t, 271
- PCNSL (primary central nervous system lymphoma).....208–209
- differential diagnosis..... 155, 168, 207, 208
- PCR. See polymerase chain reaction
- pegylated interferon alpha-2a.....83, 272–273, 273t
- peliosis hepatitis.....233
- penicillin
- bacterial pneumonia.....176
 - gingivitis.....191
 - hypersensitivity.....281
 - syphilis.....278, 280–281, 281t
- penicilliosis (penicillinosis).....176–177, 177f, 201
- pentamidine
- adverse effects.....136t, 253, 259
 - *P. jirovecii* pneumonia.....134–135
- PEP. See post-exposure prophylaxis
- percutaneous needle-stick injuries.....117–118, 119t, 121, 121t
- perforin.....20, 22
- pericardial effusion.....238–239
- periodontitis, necrotising ulcerative.....191, 191f
- peripheral blood, CD4 cell redistribution into.....27–28
- peripheral blood mononuclear cells (PBMC).....51
- peripheral nervous system diseases.....107–108, 220–221, 221t, 253
- peroxisome proliferator-activated receptor (PPAR).....103
- Pharmaceutical Benefits Scheme (PBS), Section 100.....83, 100t, 271
- phenotypes (HIV subtypes).....12–13
- phenotypic resistance testing.....54, 96
- PI. See protease inhibitors
- pioglitazone.....103, 104t, 107
- PJP. See *Pneumocystis jirovecii* pneumonia
- PLA (poly-L-lactic acid).....105
- plasmablastic lymphoma.....207
- pleural effusions.....175
- PML. See progressive multifocal leucoencephalopathy
- pneumococcal infection.....176
- Pneumocystis carinii* pneumonia. See *Pneumocystis jirovecii* pneumonia
- Pneumocystis jirovecii* pneumonia (PJP).....133–136
- clinical presentation.....133, 173, 227, 228t
 - diagnosis. 129t, 133f, 133–134, 173, 174t, 175, 180, 228t
 - immune restoration disease.....133, 290, 291t
 - management.....134–135
 - prognosis.....135
 - prophylaxis.....135–136, 174, 229, 291t, 292
- Pneumocystis jirovecii* skin lesions.....201
- pneumonia
- bacterial.....176
 - diagnostic criteria.....129t, 173, 174t
 - *Pneumocystis jirovecii* (See *Pneumocystis jirovecii* pneumonia)
- pneumonitis, lymphocytic interstitial.....181
- pneumothorax.....175
- pol gene.....24
- poly-L-lactic acid (PLA).....105
- polymerase chain reaction (PCR)
- CMV.....162
 - HBV DNA.....265
 - HCV RNA, 270
 - HIV DNA.....51
 - JCV, 167t.....167–168
 - leishmaniasis.....230
 - *P. jirovecii*.....134, 175
 - real time.....50–51
 - reverse transcriptase (RT-PCR).....11, 50, 50f, 125
 - syphilis.....278
 - VZV.....198
- polymorphisms
- chemokine receptor.....25, 39, 41, 41t, 289
 - immune restoration disease.....289
- polymyositis.....251
- polyradiculopathy, cytomegalovirus.....161
- posaconazole.....193, 193t
- post-exposure prophylaxis (PEP).....117–122
- Australian guidelines.....117, 120–121, 121t
 - cost of.....120
 - diagnostics.....122, 122t
 - management algorithms.....120t, 120–122
 - non-occupational (NPEP).....117, 119–120
 - rationale.....117
- post-kala-azar dermal leishmaniasis.....230
- post traumatic stress disorder.....244
- pravastatin.....104t, 105, 106, 237
- pregnancy
- antiretroviral therapy during.....78, 83–85
 - vertical transmission and.....39, 83–85, 114
- pre-integration complex.....11
- primary central nervous system lymphoma (PCNSL)208–209
- differential diagnosis.....155, 168, 207, 208
- primary effusion lymphoma.....207, 209
- primary HIV illness. See acute primary illness
- primary syphilis.....276, 280–281
- primate immunodeficiency viruses.....11–13, 12f
- See also simian immunodeficiency virus
- prognosis
- acute primary illness.....39, 80
 - AIDS.....40
 - at cART initiation.....78
 - cryptococcosis.....157
 - immune restoration disease.....287, 289
 - Kaposi's sarcoma.....140
 - *M. tuberculosis* infection.....151
 - MAC infection.....147
 - neurosyphilis.....279
 - nocardiosis.....178
 - *P. jirovecii* pneumonia.....135
 - pre-cART era.....77, 77f
 - progressive multifocal leucoencephalopathy.....168
 - toxoplasmosis.....155
- prognostic markers.....40–41, 80
- progressive multifocal leucoencephalopathy (PML),166–169

- clinical features..... 167
- diagnosis..... 129t, 166f, 167t, 167–168
- immune restoration disease..... 168, 290
- management..... 168–169, 169f
- prognosis..... 168

progressive outer retinal necrosis.....259

pro-inflammatory cytokines.....29

protease.....11

protease inhibitors (PI).....60–61, 63

See also specific drug

- adverse effects.....63, 67t, 185, 220, 237, 250, 254, 291
- assays.....56–57
- boosted by ritonavir (PI/r).....60, 63, 68, 114
- cardiovascular disease induced by.....105–107
- CNS penetration-effectiveness.....224t
- dosage guidelines.....63t
- drug interactions.....106, 150, 237
- historical perspective.....59, 77
- as initial therapy.....79, 79t
- injecting and recreational drug interactions.....87t–89t, 88–89
- lipodystrophy induced by.....103, 104t
- microsporidiosis.....165
- regimens based on, versus NNRTI-based.....79
- resistance mutations.....96
- therapeutic drug monitoring.....113

proteinuria.....240–241

proton pump inhibitors.....184

provirus.....9f, 11

pruritic papular eruption.....203, 204t

pseudo-membranous candidiasis.....192

Pseudomonas aeruginosa.....176, 180

psoriasis.....202–203

psoriatic arthritis.....249, 250

psychiatric symptoms.....242–248

See also specific disorder

- acute primary illness.....126t
- assessment.....244t
- treatment.....244t

psychoactive agents, drug interactions.....246, 247t, 248

psychological impact assessment, new HIV diagnosis.....73, 74t

psychotherapy.....243

psychotic disorders.....242–248

PTH (parathyroid hormone).....254

public health measures

- injecting drug users.....88
- new HIV diagnosis.....73, 75t

pulmonary disease

See respiratory disease; specific disease

pulmonary hypertension.....238

pulmonary lymphoid hyperplasia.....129t

pyomyositis.....251

pyrazinamide.....147, 147t, 150

pyrexia.....227, 228t–229t

pyrimethamine.....155, 155t, 188, 259

Q

qualitative CD4 cell defects.....28, 28f

QuantiFERON-TB Gold assay.....150, 174

quantitative CD4 cell defects.....27–28

R

radiotherapy

- anal cancer.....210–211
- Hodgkin's disease.....209
- Kaposi's sarcoma.....139

raltegravir (RAL).....61, 64

- adverse effects.....65t, 109, 185
- antimicrobial interactions with.....146t, 150
- dosage guidelines.....65t
- salvage therapy.....100t

Ramsay Hunt syndrome.....289

RANTES (regulated on activation, normal T cell expressed and secreted).....21, 41t

rapid plasmin reagin (RPR).....278, 297t

R-CHOP regimen.....208

reactive arthritis.....249–250, 250f, 260t

recombinant interleukin-2 (IL-2).....114–115

recreational drugs

See also injecting drug use; substance abuse

- antiretroviral interactions with.....88–89, 89t

regenerative villous enteropathy.....28

regulated on activation, normal T cell expressed and secreted (RANTES).....21, 41t

regulatory proteins (HIV).....9, 10t

regulatory T cells (Treg).....28

Reiter's syndrome.....249–250, 250f, 260t

renal disorders.....109, 110t, 240–241

See also specific disorder

- differential diagnosis.....240, 241t
- monitoring of.....240–241

renal transplantation.....240

replication cycle (HIV).....11

- inhibition of.....23, 30
- viral subtype and.....42

resistance. See drug resistance

respiratory disease.....173–181

See also specific disease

- in acute primary illness.....126t
- approach to.....173–175
- clinical history.....173–174
- diagnostic investigations.....174–175, 175t
- differential diagnosis.....173t, 173–174, 174t
- infectious.....176–178

retinal detachment.....258–259, 289

retinal disease.....256–259

retinal necrosis

- acute.....259, 259f
- progressive outer.....259

retinitis

- cytomegalovirus. 161–163, 256f, 256–258, 257t, 258t, 289
- toxoplasma.....155

retinoic acid.....140

retroviral rebound syndrome.....228t

- reverse transcriptase (RT)..... 11, 61
reverse transcriptase polymerase chain reaction (RT-PCR),
..... 11, 50, 50f, 125
Rev protein..... 11
Rev responsive element..... 10
rhabdomyolysis..... 251
rheumatoid arthritis..... 251
rheumatological disease..... 249–251
Rhodococcus equi infection..... 178
ribavirin..... 81, 273, 273t
ribonucleic acid (RNA)
• hepatitis C virus..... 270, 272
• HIV See HIV RNA
rifabutin
• adverse effects, 147t..... 148, 250
• *M. tuberculosis* infection..... 150
• MAC infection..... 145, 147
rifampicin
• adverse effects..... 147t
• antiretroviral interactions with..... 147
• Bartonella infections..... 233
• cryptosporidiosis..... 159
• *M. tuberculosis* infection..... 150
risk assessment. See also prognosis
• cardiovascular disease..... 105–106, 106f
• cART initiation..... 78
• HIV transmission..... 117
• mental disorders..... 242
• new HIV diagnosis..... 73, 75t, 80
• online calculators..... 77
ritonavir (RTV)..... 63
• adverse effects..... 67t
• antimicrobial interactions with..... 146t, 147, 150
• CNS penetration-effectiveness..... 224t
• FDA Black Box warnings..... 69t
• + lopinavir See lopinavir/ritonavir
• methadone interactions..... 87t
• pharmacokinetic enhancement with..... 114
• protease inhibitors boosted by (PI/r).... 60, 63, 68, 114
rituximab..... 207–208, 212
rixifaximin..... 159, 160t
RNA
• hepatitis C virus..... 270, 272
• HIV See HIV RNA
rosiglitazone..... 103, 104t, 107
rosuvastatin..... 106
RPR (rapid plasmin reagin)..... 278, 279t
RT (reverse transcriptase)..... 11, 61
RT-PCR (reverse transcriptase polymerase chain reaction),
..... 11, 50, 50f, 125
RTV. See ritonavir
- S**
Salmonella infection..... 129t, 189
salvage therapy..... 99–100, 100t
• Kaposi's sarcoma..... 140
• *P. jirovecii* pneumonia..... 135
San Joaquin Valley fever. See coccidioidomycosis
saquinavir (SQV)..... 63
• adverse effects..... 67t
• antimicrobial interactions with..... 146t, 150
• CNS penetration-effectiveness..... 224t
• contraindications..... 66t
• dosage guidelines..... 63t
• FDA Black Box warnings..... 69t
• methadone interactions..... 87t
sarcoidosis..... 290
Sarcoptes scabiei var humanus (scabies)..... 202, 204t
SAT (subcutaneous adipose tissue)..... 104t
scabies..... 202, 204t
schistosomiasis..... 290
screening programs
• anal cancer..... 211
• cervical cancer..... 210
• syphilis..... 279
SDF (stromal cell-derived factor)..... 21, 41t
seborrhoeic dermatitis..... 202
secondary syphilis..... 276–277, 280–281
Section 100 (PBS)..... 83, 100t, 271
selective serotonin reuptake inhibitors (SSRIs)
..... 243, 245, 247t, 248
sensory neuropathy (SN)..... 107–108, 220–221, 221t
septic arthritis..... 250
seroprevalence, statistics on..... 118t
seven-transmembrane receptors..... 10, 21
sex hormone disorders..... 253t, 254–255
sexually transmissible infections (STI)
See also specific infection
• role in HIV transmission..... 38, 118–119
• testing for..... 122, 122t
sexual transmission..... 13–14, 37–38, 38t
See also heterosexual transmission; homosexual
transmission
• hepatitis C virus..... 270, 274
• herpes virus infection and..... 38, 199
• post-exposure prophylaxis... 118–119, 119t, 121, 121t
sex workers
• HIV seroprevalence..... 118t
• human papillomavirus infection in..... 209
Shigella infection..... 189–190
shingles..... 198–199
sicca syndromes..... 251, 260
SIL (squamous intraepithelial lesions)..... 210–211
SILCAAT study..... 61, 115
simian immunodeficiency virus (SIV)..... 11
• CCR5 receptors..... 37
• CD4 cell defects induced by..... 27
• CD8 cell response and..... 21, 22
• HEPS and..... 25
• immune activation..... 28
• non-progression..... 30
• oral transmission of..... 39
simvastatin..... 106
sinusitis..... 128, 180t, 180–181
SIV
See simian immunodeficiency virus

- SI (syncytium inducing) variants..... 42
- Sjogren's syndrome..... 251
- skin conditions
See dermatological conditions; specific condition
- skin exposure..... 118, 121, 121t
- SMART (Strategies for Management of Antiretroviral Therapy) study..... 59, 78, 114, 115, 237
- smoking..... 174, 181, 211
- SN (sensory neuropathy)..... 107–108, 220–221, 221t
- social phobia..... 244
- SP (single positive)..... 19f, 20f
- specificity and sensitivity
• HIV screening assays..... 50, 51, 60, 126
• syphilis testing..... 278–279
• therapeutic drug monitoring..... 57
- spinal cord diseases..... 219, 220t
- splenomegaly..... 262
- spondyloarthropathy..... 249
- sputum specimen
• differential diagnosis using..... 175
• *M. tuberculosis* infection..... 149
• *P. jirovecii* pneumonia..... 133–134
- squamous cell carcinoma..... 211
- squamous intraepithelial lesions (SIL)..... 210–211
- SQV. See saquinavir
- SSRIs (selective serotonin reuptake inhibitors)
..... 243, 245, 247t, 248
- Stanford HIV resistance database..... 95
- Stanford V regimen..... 209
- Staphylococcus aureus*
• arthritis..... 250
• endocarditis..... 239
• methicillin-resistant..... 191
• pneumonia..... 176
• sinusitis..... 180
- START study..... 60
- statins. See also specific drug
• drug interactions..... 237
• hypercholesterolaemia..... 106, 237
• lipodystrophy..... 104t, 105
- stavudine (d4T)..... 61
• adverse effects..... 103, 105–107, 220
• CNS penetration-effectiveness..... 224t
• contraindications..... 61, 66t, 80t, 84, 119
• FDA Black Box warnings..... 69t
• methadone interaction..... 87t
• resistance mutations..... 96
- steatohepatitis..... 108, 185
- Stevens-Johnson syndrome..... 203–204, 205t
- STI. See sexually transmissible infections; specific infection
- St John's wort..... 247t
- stomach illness. See gastrointestinal symptoms; specific disease
- stool examination
• bacterial infection..... 189–190
• diarrhoea..... 184–185
• parasitic infection..... 159, 165, 188
- Strategies for Management of Antiretroviral Therapy (SMART) study..... 59, 78, 114, 115, 237
- street drugs
See also injecting drug use; substance abuse
• antiretroviral interactions with..... 87t–89t, 88–89
- Streptococcus pneumoniae*..... 176, 180
- stress disorder..... 244
- stromal cell-derived factor (SDF)..... 21, 41t
- strongyloidiasis..... 290
- structural proteins (HIV)..... 9, 9f, 10t, 24
- structured treatment interruption..... 81, 100, 114
- subcutaneous adipose tissue (SAT)..... 104t
- substance abuse, 246. See also injecting drug use
• antiretroviral interactions with..... 88–89, 89t
• mental disorders and..... 242
- suicidal ideation..... 243, 273
- sulphadiazine..... 155, 155t, 259
- sulphamethoxazole-trimethoprim. See cotrimoxazole
- superinfection (HIV)..... 38
- support services, new HIV diagnosis..... 73, 74t
- surrogate markers, of disease progression..... 40–41
See also specific test
- survival rates. See also prognosis
• immune restoration disease..... 289
• influence of cART on..... 130
• *M. tuberculosis* infection..... 151
- sustained virological response (SVR)..... 272
- symptomatic HIV infection (non-AIDS)..... 39, 42–43, 78, 127–128
- syncytium-forming ability..... 10, 42
- syncytium inducing (SI) variants..... 42
- syphilis..... 186, 276–282
• clinical presentation..... 276t, 276–278
• contact tracing..... 282
• diagnosis..... 278–280, 279t
• epidemiology..... 276
• ocular..... 260, 260t, 278
• re-infection..... 278
• treatment..... 280–282, 281t
- systemic infections..... 230–234
See also specific infection
- systemic symptoms..... 227–229
See also specific symptom
- ## T
- T-20
See enfuvirtide
- tacrolimus..... 168
- TAMs (thymidine analogue mutations)..... 96
- Tat protein..... 11, 22, 23, 24, 26
- TB (tuberculosis)..... 149, 173–174
See also *Mycobacterium tuberculosis* infection
- 3TC. See lamivudine
- T cells
• cytotoxic..... 19–20, 25, 30, 56t
• development of..... 19, 19f, 27, 28
• effector responses..... 19–20, 20f, 22
• gamma-delta..... 29
• helper (CD4) (See CD4 cells)
• killer (CD8) (See CD8 cells)
• memory (See memory T cells)

- qualitative defects in.....28
- regulatory (Treg).....28
- subset assays.....56, 56t
- T cell exhaustion.....28
- T cell receptor (TcR).....19, 28
- T-cell receptor excision circles (TREC).....27, 40
- T cell vaccines.....69, 115
- TDF
 - See tenofovir disoproxil fumarate
- TDM
 - See therapeutic drug monitoring
- telbivudine.....268
- TEN (toxic epidermal necrolysis).....203–204, 205t
- tenofovir disoproxil fumarate (TDF).....61
 - adverse effects.....66t
 - bone disease induced by.....109
 - CNS penetration-effectiveness.....224t
 - contraindications.....80t
 - dosage guidelines.....62t
 - + emtricitabine (Truvada™).....60, 61, 62t, 66t, 119
 - + emtricitabine + efavirenz (Atripla™).....61, 62t, 66t
 - FDA Black Box warnings.....69t
 - hepatitis B co-infection.....78–79, 83, 108, 267–268, 290
 - methadone interactions.....87t
 - post-exposure prophylaxis.....119
 - pregnant patients.....84
 - renal toxicity.....109, 240
 - resistance mutations.....96
- tertiary syphilis.....277
- testicular cancer.....211–212
- testosterone.....255
- tetherin.....11
- tetramer assays.....21–22, 23, 56t
- TGA (Therapeutic Drugs Administration), antiretroviral agents approved by.....61, 100t
- thalidomide.....30t, 165, 192–194
- Th1 cells.....19
- Th2 cells.....19
- therapeutic drug monitoring (TDM).....56–57, 113–114
 - gastrointestinal symptoms and.....184
 - limitations of.....113
 - virological failure and.....99
- Therapeutic Drugs Administration (TGA), antiretroviral agents approved by.....61, 100t
- therapeutic failure
 - antiretroviral.....94–95, 95t, 97–99, 114
 - cytomegalovirus disease.....163
 - syphilis.....282
- Therapeutics Research, Education and AIDS Training in Asia (TREAT Asia) HIV Observational Database.....125
- thiazolidinediones.....103, 104t, 107, 254
- thrombocytopenia.....261
- thromboembolic disease.....262
- thymic function
 - boosting.....30–31
 - in HIV-infected patients.....27–28
 - immune restoration and.....287
 - T cell development.....19, 19f
- thymic stromal lymphopoietin (TSLP).....28
- thymidine analogue mutations (TAMs).....96
- thyroid disease.....253t, 254, 290
- thyrotoxicosis.....254, 255
- tinea corporis.....200
- tinea cruris.....200
- tipranavir (TPV).....61, 63
 - adverse effects.....67t, 185
 - antimycobacterial agents combined with.....146t
 - CNS penetration-effectiveness.....224t
 - dosage guidelines.....63t
 - FDA Black Box warnings.....69t
 - methadone interactions.....87t
 - salvage therapy.....100t
- TNF (tumour necrosis factor).....40, 250
- toll like receptors (TLR).....19
- torsade de pointes.....239
- toxic epidermal necrolysis (TEN).....203–204, 205t
- toxoplasmosis.....154–155
 - chorioretinitis.....259
 - clinical presentation.....154
 - diagnosis.....129t, 154f, 154–155, 173
 - immune restoration disease.....290, 291t
 - management.....155, 155t
 - prognosis.....155
 - prophylaxis.....155, 174
- TP-PA (*Treponema pallidum* particle agglutination),278–279
- TPV
 - See tipranavir
- TRAIL ligand.....29
- transcription (HIV).....11
 - host genetics and.....25, 39
 - inhibition of.....23
- transcription factors.....11
- transmission (HIV).....37–39
 - by bodily fluids.....39
 - herpesvirus type 8.....138
 - HIV subtypes.....12, 42
 - injecting drug use.....12–14, 86, 118
 - mother-to-child.....39, 83–85, 114, 129
 - non-occupational exposure.....118–122, 119t
 - occupational exposure.....117–118, 120–122
 - prevention of (See post-exposure prophylaxis)
 - probability of.....37, 37f, 117, 119t
 - sexual See sexual transmission
- TREAT Asia HIV Observational Database.....125
- treatment discontinuation.....81, 100, 114
- treatment outcome, strategies to improve.....113–115
- TREC (T-cell receptor excision circles).....27, 40
- Treg (regulatory T cells).....28
- Treponema pallidum* antigen index.....279
- Treponema pallidum* particle agglutination (TP-PA).....278–279
- Trichophyton rubrum*.....200
- tricyclic antidepressants.....247t
- TRIM5alpha (human tripartite motif 5 alpha) protein.....11, 30
- trimethoprim-sulphamethoxazole. See cotrimoxazole
- Trizivir™ (zidovudine + lamivudine + abacavir).....61, 64, 223
- Trofile™ assay.....53f, 54
- tropisms (HIV).....10, 42, 64, 96
- Truvada™ (tenofovir + emtricitabine).....60, 61, 62t, 66t, 119

- TSG101 (tumour suppressor gene 101)..... 11
 TSLP (thymic stromal lymphopoietin).....28
 tuberculin skin test (TST or Mantoux test)..... 149–150, 174
 tuberculosis (TB)..... 149, 173–174
 See also *s* infection
 tumour necrosis factor (TNF)..... 40, 250
 tumour suppressor gene 101 (TSG101)..... 11
 tyrosine-methionine-aspartate-aspartate (YMDD) motif... 267
- U**
 ulceration
 • oesophageal..... 184, 193–194
 • oral aphthous..... 191–192
 ulcerative colitis..... 185
 undifferentiated spondyloarthritis..... 249
 US Department of Health and Human Services (DHHS)
 • antiretroviral guidelines. 59–61, 64, 77, 79, 85–86, 113
 • TB testing guidelines..... 150
 US Food and Drug Administration (FDA)
 • antiretroviral agents approved by..... 61, 63
 • Black Box warnings for antiretrovirals..... 68, 69t
 • hepatitis drugs approved by..... 82–83
 US Multicenter AIDS Cohort Study (MACS)..... 94, 125, 211
 US National Surveillance data..... 118
 US Public Health Service, 2002 guidelines for prevention
 of opportunistic infections..... 157
 untranslated region (UTR)..... 41t
 urethritis..... 249
 uridine..... 104t, 105
 urinalysis..... 240–241
 urogenital infections, reactive arthritis triggered by..... 250
 uveitis..... 258, 260, 260t, 289
 • immune reconstitution..... 258
 • syphilitic..... 278
- V**
 vaccines
 • HIV..... 13, 68–69, 115
 • human papilloma virus..... 210
 • pneumococcal..... 176
 • varicella..... 198
 vacuolar myelopathy (VM)..... 219, 220t
 valaciclovir..... 38, 198–199, 199t
 valganciclovir..... 162–163, 257, 257t
 Valley fever
 See coccidioidomycosis
 vancomycin-resistant Enterococcus (VRE)..... 191
 vanishing bile duct syndrome..... 186
 varicella zoster virus (VZV) infection..... 198–199, 259, 289
 vascular endothelial changes, HIV-induced..... 237
 vasculitis..... 251
 VAT (visceral adipose tissue)..... 104t, 105
 ventricular tachyarrhythmia..... 239
 ventriculoencephalitis, cytomegalovirus..... 161–162
 vertical transmission..... 39, 83–85, 114, 129
 very low density lipoprotein (VLDL)..... 106t
 Vif protein..... 11
 viral entry (HIV)..... 10–11, 63, 64f
 viral envelope (HIV)..... 9, 9f, 24
 viral escape (HIV)..... 25–26, 26f
 viral factors, influencing disease progression..... 42
 viral fitness, HIV subtypes..... 12
 viral infections
 See also specific infection
 • dermatological..... 197–200
 viral latency..... 26, 31
 • antiretroviral therapy and..... 50–60
 viral load (VL)
 • during acute primary illness..... 39
 • blips..... 98
 • children..... 86
 • determination of..... 50–51
 • disease progression and..... 22, 24, 25, 40
 • gender differences in..... 42, 78
 • HIV-1-associated dementia..... 224
 • JCV..... 168
 • plasma, as surrogate marker..... 40–41, 80, 97–98
 • prognosis by, pre-cART era..... 77, 77f
 • risk of transmission and..... 37, 117, 118
 • syphilis and..... 277
 • therapeutic monitoring using..... 93, 97–98
 • therapies reducing..... 30
 See also antiretroviral therapy
 • vertical transmission and..... 39, 83–85
 viral myocarditis..... 238, 238f
 viral proteins. See also HIV proteins; specific protein
 functions of..... 11
 viral set point..... 22, 40
 virological diagnostics..... 24, 49–54, 85
 virological failure..... 95, 97–99, 114
 virtual phenotyping..... 54, 96
 visceral adipose tissue (VAT)..... 104t, 105
 visceral leishmaniasis (VL)..... 228t, 230
 visual disturbance
 See ophthalmic disease; specific disease
 vitreomacular traction syndrome..... 289
 vitritis, cytomegalovirus..... 161, 289
 VL
 See viral load
 VL (visceral leishmaniasis)..... 228t, 230
 VLDL (very low density lipoprotein)..... 106t
 VM (vacuolar myelopathy)..... 219, 220t
 voriconazole..... 141–142, 143t, 193, 193t
 Vpr protein..... 11
 Vpu protein..... 11
 VRE (vancomycin-resistant Enterococcus)..... 191
 vulvovaginal candidiasis..... 200
 VZV (varicella zoster virus) infection..... 198–199, 259, 289
- W**
 warts (HPV infection)..... 199–200, 209, 290
 wasting syndrome..... 129t, 251, 254–255
 weight loss..... 227
 Western Blot assay..... 24, 49f, 49–50, 125
 ‘wild type’ genotype..... 100, 114

window period..... 49, 126
women
• disease progression in.....42, 78, 83
• HIV epidemic in..... 13f, 13–14
• treatment guidelines.....83
Women’s Interagency HIV Study.....94

X

xerosis.....202

Y

YMDD (tyrosine-methionine-aspartate-aspartate) motif
.....267

Z

zalcitabine (ddC).....61, 107, 220
zidovudine (ZDV or azidothymidine or AZT).....61
• adverse effects.....66t, 273
• cardiovascular disease induced by..... 105–107
• CNS penetration-effectiveness.....224t
• contraindications.....66t, 80t
• dosage guidelines.....62t, 85
• FDA Black Box warnings.....69t
• historical perspective.....59, 77
• immune reconstitution after.....145
• infants.....84, 85
• lactic acidosis induced by.....107
• + lamivudine (Combivir™).....61, 62t, 66t, 119
• + lamivudine + abacavir (Trizivir™).....61, 64, 223
• lipodystrophy induced by.....103
• methadone interactions.....87t, 88
• myopathy induced by.....251
• post-exposure prophylaxis.....119
• pregnant patients.....83–85
• resistance mutations.....96